Envoy Medical (COCH) Net Cash Flow (2021 - 2026)

Envoy Medical (COCH) has 6 years of Net Cash Flow data on file, last reported at $21.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 12254.24% year-over-year to $21.5 million; the trailing twelve-month figure through Mar 2026 stood at $19.9 million (up 5378.85% YoY), and the FY2025 full-year result was -$1.7 million, down 237.67% from the prior year.
• Net Cash Flow grew to $21.5 million in Q1 2026, from $183000.0 in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $21.5 million in Q1 2026 to a low of -$12.6 million in Q4 2023.
• A 5-year average of $1.4 million and a median of -$22740.0 in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow sank 2904.76% in 2023 and soared 12254.24% in 2026, its largest moves.
• Tracing COCH's Net Cash Flow over 5 years: stood at -$420000.0 in 2022, then slumped by 2904.76% to -$12.6 million in 2023, then jumped by 108.4% to $1.1 million in 2024, then sank by 82.74% to $183000.0 in 2025, then soared by 11655.74% to $21.5 million in 2026.
• Business Quant data shows COCH's Net Cash Flow at $21.5 million in Q1 2026, $183000.0 in Q4 2025, and -$1.7 million in Q3 2025.